All In Biotech

Drug Trial Radar · NCT06941844

A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)

A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Emerge

Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 149 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

149

Actual

Start

Apr 14, 2025

Primary completion

May 20, 2026

Study completion Feb 2027

Sponsor

Lead sponsor
Definium Therapeutics US, Inc.Industry
Sponsor type
Industry
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge

Conditions

  • Major Depressive Disorder

Interventions

  • PlaceboOther

    A substance that is designed to have no therapeutic value

  • DT120Drug

    A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6Time frame: Baseline to Week 6

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • Preferred Research Partners, Inc

    Little Rock, Arkansas

  • Kadima Neuropsychiatry Institute

    La Jolla, California

  • Psychedelic Science Institute

    Santa Monica, California

  • Mountain View Clinical Research, Inc

    Denver, Colorado

  • CNS, LLC (Jacksonville)

    Jacksonville, Florida

  • CNS, LLC (Orlando)

    Orlando, Florida

  • Charter Research

    Orlando, Florida

  • Uptown Research Institute (URI), LLC

    Chicago, Illinois

  • Sheppard Pratt

    Baltimore, Maryland

  • Adams Clinical Boston

    Boston, Massachusetts

  • Adams Clinical

    Watertown, Massachusetts

  • University of Missouri

    Columbia, Missouri

  • Cenexel HRI

    Berlin, New Jersey

  • Adams Clinical Harlem

    New York, New York

  • Columbia - New York State Psychiatric Institute

    New York, New York

  • Neuro-Behavioral Clinical Research

    Canton, Ohio

  • University of Cincinnati

    Cincinnati, Ohio

  • Adams Clinical Philadelphia

    Philadelphia, Pennsylvania

  • CNS, LLC (Memphis)

    Memphis, Tennessee

  • Austin Clinical Trial Partners

    Austin, Texas

  • Cedar Clinical Research

    Murray, Utah

  • Memory Clinic, Inc

    Bennington, Vermont

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.